Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques

Robert Bies, Marc R. Gastonguay, Kim C. Coley, Patricia D. Kroboth, Bruce G. Pollock

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: The authors examine the usefulness of population pharmacokinetics coupled with electronic compliance monitoring in evaluating consistency of exposure to pharmacotherapy. Adherence to pharmacotherapy can have a significant impact on drug response, especially in the treatment of schizophrenia and depression. Previous studies evaluating antipsychotics identified schizophrenic individuals with poor pharmacotherapy adherence as having a higher risk of rehospitalization. Other investigators have shown a relationship between pattern of taking selective serotoninreuptake inhibitors (SSRIs) and probability of a positive outcome. Therefore, it is important to measure adherence patterns in clinical trials evaluating these treatments and to incorporate this information into the research findings. Methods: Two multisite trials with atypical antipsychotics and antidepressants were simulated to evaluate, by use of population pharmacokinetic methods, the impact of electronic monitoring on measuring consistency of exposure to pharmacotherapy. One of the trials is ongoing and evaluates exposure to atypical antipsychotics, and the other is a proposed trial that examines exposure to an SSRI. Results: Erratic exposurepatterns were detected with population pharmacokinetic techniques in the absence of Electronic Medication Event Monitoring (MEMS™) data. In our simulations, the use of electronic monitoring improved the identification of atypical exposure by population pharmacokinetics both for the atypical antipsychotics and SSRIs. Conclusion: Our simulations demonstrate the potential usefulness of the combination of population pharmacokinetics with electronic monitoring as a robust method for accurately and precisely capturing both magnitude and consistency of pharmacotherapy exposure.

Original languageEnglish (US)
Pages (from-to)696-705
Number of pages10
JournalAmerican Journal of Geriatric Psychiatry
Volume10
Issue number6
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Pharmacokinetics
Antipsychotic Agents
Drug Therapy
Population
Second-Generation Antidepressive Agents
Micro-Electrical-Mechanical Systems
Compliance
Schizophrenia
Research Personnel
Clinical Trials
Depression
Therapeutics
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. / Bies, Robert; Gastonguay, Marc R.; Coley, Kim C.; Kroboth, Patricia D.; Pollock, Bruce G.

In: American Journal of Geriatric Psychiatry, Vol. 10, No. 6, 2002, p. 696-705.

Research output: Contribution to journalArticle

Bies, Robert ; Gastonguay, Marc R. ; Coley, Kim C. ; Kroboth, Patricia D. ; Pollock, Bruce G. / Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. In: American Journal of Geriatric Psychiatry. 2002 ; Vol. 10, No. 6. pp. 696-705.
@article{cb6c6d5bde3d44ba9c5f89435025a6a0,
title = "Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques",
abstract = "Objective: The authors examine the usefulness of population pharmacokinetics coupled with electronic compliance monitoring in evaluating consistency of exposure to pharmacotherapy. Adherence to pharmacotherapy can have a significant impact on drug response, especially in the treatment of schizophrenia and depression. Previous studies evaluating antipsychotics identified schizophrenic individuals with poor pharmacotherapy adherence as having a higher risk of rehospitalization. Other investigators have shown a relationship between pattern of taking selective serotoninreuptake inhibitors (SSRIs) and probability of a positive outcome. Therefore, it is important to measure adherence patterns in clinical trials evaluating these treatments and to incorporate this information into the research findings. Methods: Two multisite trials with atypical antipsychotics and antidepressants were simulated to evaluate, by use of population pharmacokinetic methods, the impact of electronic monitoring on measuring consistency of exposure to pharmacotherapy. One of the trials is ongoing and evaluates exposure to atypical antipsychotics, and the other is a proposed trial that examines exposure to an SSRI. Results: Erratic exposurepatterns were detected with population pharmacokinetic techniques in the absence of Electronic Medication Event Monitoring (MEMS™) data. In our simulations, the use of electronic monitoring improved the identification of atypical exposure by population pharmacokinetics both for the atypical antipsychotics and SSRIs. Conclusion: Our simulations demonstrate the potential usefulness of the combination of population pharmacokinetics with electronic monitoring as a robust method for accurately and precisely capturing both magnitude and consistency of pharmacotherapy exposure.",
author = "Robert Bies and Gastonguay, {Marc R.} and Coley, {Kim C.} and Kroboth, {Patricia D.} and Pollock, {Bruce G.}",
year = "2002",
doi = "10.1097/00019442-200211000-00008",
language = "English (US)",
volume = "10",
pages = "696--705",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques

AU - Bies, Robert

AU - Gastonguay, Marc R.

AU - Coley, Kim C.

AU - Kroboth, Patricia D.

AU - Pollock, Bruce G.

PY - 2002

Y1 - 2002

N2 - Objective: The authors examine the usefulness of population pharmacokinetics coupled with electronic compliance monitoring in evaluating consistency of exposure to pharmacotherapy. Adherence to pharmacotherapy can have a significant impact on drug response, especially in the treatment of schizophrenia and depression. Previous studies evaluating antipsychotics identified schizophrenic individuals with poor pharmacotherapy adherence as having a higher risk of rehospitalization. Other investigators have shown a relationship between pattern of taking selective serotoninreuptake inhibitors (SSRIs) and probability of a positive outcome. Therefore, it is important to measure adherence patterns in clinical trials evaluating these treatments and to incorporate this information into the research findings. Methods: Two multisite trials with atypical antipsychotics and antidepressants were simulated to evaluate, by use of population pharmacokinetic methods, the impact of electronic monitoring on measuring consistency of exposure to pharmacotherapy. One of the trials is ongoing and evaluates exposure to atypical antipsychotics, and the other is a proposed trial that examines exposure to an SSRI. Results: Erratic exposurepatterns were detected with population pharmacokinetic techniques in the absence of Electronic Medication Event Monitoring (MEMS™) data. In our simulations, the use of electronic monitoring improved the identification of atypical exposure by population pharmacokinetics both for the atypical antipsychotics and SSRIs. Conclusion: Our simulations demonstrate the potential usefulness of the combination of population pharmacokinetics with electronic monitoring as a robust method for accurately and precisely capturing both magnitude and consistency of pharmacotherapy exposure.

AB - Objective: The authors examine the usefulness of population pharmacokinetics coupled with electronic compliance monitoring in evaluating consistency of exposure to pharmacotherapy. Adherence to pharmacotherapy can have a significant impact on drug response, especially in the treatment of schizophrenia and depression. Previous studies evaluating antipsychotics identified schizophrenic individuals with poor pharmacotherapy adherence as having a higher risk of rehospitalization. Other investigators have shown a relationship between pattern of taking selective serotoninreuptake inhibitors (SSRIs) and probability of a positive outcome. Therefore, it is important to measure adherence patterns in clinical trials evaluating these treatments and to incorporate this information into the research findings. Methods: Two multisite trials with atypical antipsychotics and antidepressants were simulated to evaluate, by use of population pharmacokinetic methods, the impact of electronic monitoring on measuring consistency of exposure to pharmacotherapy. One of the trials is ongoing and evaluates exposure to atypical antipsychotics, and the other is a proposed trial that examines exposure to an SSRI. Results: Erratic exposurepatterns were detected with population pharmacokinetic techniques in the absence of Electronic Medication Event Monitoring (MEMS™) data. In our simulations, the use of electronic monitoring improved the identification of atypical exposure by population pharmacokinetics both for the atypical antipsychotics and SSRIs. Conclusion: Our simulations demonstrate the potential usefulness of the combination of population pharmacokinetics with electronic monitoring as a robust method for accurately and precisely capturing both magnitude and consistency of pharmacotherapy exposure.

UR - http://www.scopus.com/inward/record.url?scp=84903187300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903187300&partnerID=8YFLogxK

U2 - 10.1097/00019442-200211000-00008

DO - 10.1097/00019442-200211000-00008

M3 - Article

C2 - 12427578

AN - SCOPUS:0036845047

VL - 10

SP - 696

EP - 705

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 6

ER -